[Examination of the change in plasma concentration of OH-flutamide in low-dose flutamide (250 mg/day) monotherapy for prostate cancer patients].
An examination of the change in plasma concentration of OH-flutamide in low-dose flutamide (250 mg/day) monotherapy for 5 prostate cancer patients was performed. We treated 5 patients diagnosed with prostate cancer between September and November 2002. The plasma concentrations of OH-flutamide, PSA and AST/ALT were measured before and after low-dose flutamide monotherapy was started. The plasma concentrations of OH-flutamide were stable in the third day after medication was started, and even when compared with the plasma concentrations of OH-flutamide 375 mg/day, there was no significant difference. Although at the observation period was short, PSA fell favorably in all patients. The AST/ALT were in the normal range in all patients. The low-does flutamide therapy has been one of medical treatments if its safety and effectiveness has been demonstrated.
Harano
Masahiko
M
Kano Hospital.
Kano
Masako
M
Hida
Tsukasa
T
Fujisawa
Yasuhito
Y
Kano
Motonori
M
D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000726:Androgen Antagonists / Q000008:administration & dosage*; D001219:Aspartate Aminotransferases / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005485:Flutamide / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000097:blood*; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood* / Q000188:drug therapy; D012016:Reference Values
D000726:Androgen Antagonists; C014290:hydroxyflutamide; D005485:Flutamide; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D017430:Prostate-Specific Antigen